Priyanka(Surana)SharmaMD

Oncology • Westwood, KS

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine, Department of Internal Medicine

Join to view full profile

Dr. Sharma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sharma's full profile

Already have an account?

Office
2330 Shawnee Mission Pkwy
Ste 210
Westwood, KS 66205
Phone+1 913-588-6029

Fax+1 913-588-9822

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Kansas School of MedicineChief Residency, Internal Medicine, 2001 - 2002
University of Kansas School of MedicineResidency, Internal Medicine, 1999 - 2001
Baroda Medical CollegeClass of 1997

Certifications & Licensure

KS State Medical License 2001 - 2025
MO State Medical License 2021 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Start of enrollment: 2009 Mar 01
Terminated
Phase 2
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Start of enrollment: 2009 May 01
Completed
Phase 2
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression Start of enrollment: 2009 Jul 01
Completed
Phase 2
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer Start of enrollment: 2010 Jul 01
Withdrawn
Phase 2
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Start of enrollment: 2011 Feb 01
Unknown status
Phase 2
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry Start of enrollment: 2011 Mar 22
Recruiting
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer Start of enrollment: 2015 Jul 01
Completed
Phase 2
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer Start of enrollment: 2022 Mar 28
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer Start of enrollment: 2023 Sep 15
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

442 citations
Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Fergus J. Couch, Steven N. Hart, Priyanka Sharma, Amanda E. Toland, Xianshu Wang
Journal of Clinical Oncology. 2015-02-01
170 citations
Biology and Management of Patients With Triple-Negative Breast Cancer
Priyanka Sharma
The Oncologist. 2016-09-01
204 citations
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations
Timothy R. Rebbeck, Tara M. Friebel, Eitan Friedman, Ute Hamann, Dezheng Huo
Human Mutation. 2018-05-01

Journal Articles

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Amanda Amin, Jamie Wagner, Qamar J Khan, Roy A Jensen, Joshua M Mammen, Priyanka Sharma, Jennifer R Klemp, Clinical Cancer Research

Lectures

Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast canc...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Summing It Up: Neoadjuvant Therapy in Triple-Negative DiseaseApril 6th, 2023
Focus on Optimizing Use of CDK4/6 Inhibitors in Metastatic HR+ Breast CancerMarch 8th, 2023
Addition of Veliparib to Cisplatin in Advanced Triple-Negative Breast Cancer with BRCA-like and Non–BRCA-like PhenotypeJanuary 23rd, 2023
Join now to see all